NCT06007846招募中2 期
A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 4
- 主要终点
- Patients Progression Free Survival at 6 months
研究概览
简要总结
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 or older.
- •Patients have newly diagnosed and previously untreated, histologically or radiologically confirmed hepatocellular carcinoma with at least one lesion that is measurable by RECIST 1.1 criteria. A prior HCC lesion that was treated surgically or by radiation is allowed as long as it was at least 2 years or more from the current HCC diagnosis.
- •Patient's cancer must be deemed locally advanced and unresectable as per the consensus of the Inova Multidisciplinary Cancer Care Conference.
- •Patients must have a Child-Pugh cirrhosis score of B7 or greater and deemed not a candidate for aggressive systemic treatment.
- •Eastern Cooperative Oncology Group Performance Status of 0-
- •Patients must have adequate blood counts and organ function.
- •Memantine is harmful to the human fetus. For this reason, sexually active males with partners of childbearing potential must agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study. Women of child bearing potential must have a negative serum pregnancy test result within 24 hours prior to initiation of study treatment. They must also agree to use agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study.
- •Patients must demonstrate ability to understand and the willingness to sign a written informed consent document.
- •Men and women, regardless of race, ethnic group or sexual orientation are eligible for this study.
排除标准
- •Patients with Child-Pugh A cirrhosis.
- •Female patients who are pregnant or breast-feeding.
- •Concomitant illness or history that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.
- •Life-threatening intercurrent illness.
- •Anticipated poor compliance.
- •Subject is enrolled in a separate interventional clinical trial.
- •Active tuberculosis.
- •Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
- •Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
- •Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry for at least 10 days prior to study entry.
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment.
- •Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
- •Patients undergoing other anti-cancer treatment. Palliative radiation for symptom control will be allowed while on protocol.
研究组 & 干预措施
Arm 1
Experimental
干预措施: Namenda (Drug)
结局指标
主要结局
Patients Progression Free Survival at 6 months
时间窗: 6 months from the start of treatment
The response and progression will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. The progression of the disease is defined as at least a 20% increase in the sum of the Longest Diameter LD of target lesions, taking the smallest sum LD recorded as reference since the treatment started or the appearance of one or more new lesions or death due to disease without objective evidence of progression.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)Peripheral Arterial DiseaseCritical Limb IschemiaNCT05358353ReFlow Medical, Inc.130
招募中
2 期
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsNon-clear Renal Cell CarcinomaNCT05768464The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School30
招募中
2 期
Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic AnemiaTPO Receptor AgonistsAplastic AnemiaNCT06613880Institute of Hematology & Blood Diseases Hospital, China48
Unknown
3 期
Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut SyndromeDravet SyndromeLennox Gastaut SyndromeNCT04611438Yonsei University107
招募中
2 期
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaDiffuse Large B Cell LymphomaNCT05940064Peng Liu30